Komori
Kaken Pharmaceutical (4521) · InitiativeAdvanced

Developing Creative Talent

First written in FY2017. 3 of 6 entries say "Restated". Latest entry: FY2026.

6entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2019RestatedFY20222017: 120172018: 120182019: 120192020: 020202021: 120212022: 120222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Human Capital Investment, Development and Retention of Diverse TalentA theme 428 companies write about · 3 as a headwind · 438 as a tailwind

The whole theme swung hardest in 2020: 5 of 40 companies on the "Worse" side.

109 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 193 companies compared. The sentences above are computed from all 193.Comparing 200 of the theme's 441 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「Percentage of female employees in management positions: Target: at least 7.0% by the end of fiscal 2025; Fiscal 2025 actual: 7.2% / Percentage of male employees taking childcare leave and number of days taken: Target: a take-up rate of at least 80.0% and an average of at least 9 days by fiscal 2025; Fiscal 2025 actual: take-up rate of 82.9%, average of 33.4 days taken」

    Regarding human capital initiatives, the percentage of women in management positions was 7.2%, exceeding the 7.0% target, while the rate of male employees taking childcare leave and the average number of days taken also exceeded their targets. Metrics including training hours and the proportion of experienced hires were also disclosed as fiscal-year results.
  2. FY2022RestatedAnnual report

    「By promoting people-centered management, we will improve the productivity of all employees and develop next-generation leaders and talent capable of delivering results globally.」

    The company continues to target higher productivity among all employees and the development of next-generation leaders and global talent.
  3. FY2021AdvancedAnnual report

    「By promoting people-centered management, we will improve the productivity of all employees and develop next-generation leaders and talent capable of delivering results globally. We will also respond flexibly to new ways of working and continue improving the work environment so that all employees can fully realize their potential.」

    The scope of initiatives has expanded beyond the existing development of next-generation leaders to include the development of global talent, people-centered management, responses to new ways of working, and improvements to the workplace environment.
  4. FY2019RestatedAnnual report

    「Across the Group, we worked to strengthen our human capital, including by focusing on developing leaders who will drive the next generation.」

    The priority measure of developing creative talent continued through the development of next-generation leaders and the strengthening of human capital.
  5. FY2018RestatedAnnual report

    「We will work to develop creative talent suited to an era of transformation.」

    Talent development continues to be identified as a priority measure in the medium-term management plan.
  6. FY2017First statedAnnual report

    「We will work to develop creative talent suited to an era of transformation.」

    Talent development was explicitly identified as one of the priority measures in the medium-term management plan.
Moved together

"Pharmaceutical licensing in Japan and overseas" moved the same way as this thread, in the same document, in 2 of its 6 moves.

222222★123456
  1. ★This thread
  2. 1Pharmaceutical licensing in Japan and overseas2×
  3. 2Continuation of R&D investment2×
  4. 3Strengthening the New Drug Pipeline and Accelerating Research and Development2×
  5. 4Clinical development pipeline progress2×
  6. 5Implementation of Shareholder Returns2×
  7. 6Maximising Product Value and Strengthening the Sales Platform2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.